When was bpc 157 created

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: BPC-157 was first synthesized and studied in the early 1990s by researchers at the University of Zagreb, Croatia. The peptide was developed as part of research into the protective and regenerative properties of gastric juice.

Key Facts

BPC-157 was first created in the early 1990s
Developed by researchers at the University of Zagreb, Croatia
Stands for Body Protection Compound-157
Derived from a protein found in human gastric juice
Over 160 scientific studies have explored its healing effects as of 2023

Overview

BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. It was first synthesized in the early 1990s by a research team at the University of Zagreb, Croatia, led by Dr. Predrag Sikirić, as part of investigations into gastrointestinal healing and tissue repair.

The compound was designed to mimic the protective effects of natural gastric juice, particularly its role in ulcer healing and tissue regeneration. Since its creation, BPC-157 has been the subject of extensive preclinical research, showing promise in accelerating wound healing, reducing inflammation, and supporting tendon and ligament repair.

1990 marks the first documented synthesis of BPC-157 in laboratory settings, initiating a series of animal studies on its regenerative properties.
The peptide is a fragment of a larger protein found in human gastric juice, specifically in the stomach’s protective mucus layer.
Initial studies focused on its ability to heal gastric ulcers and prevent damage from nonsteroidal anti-inflammatory drugs (NSAIDs).
Unlike many experimental compounds, BPC-157 demonstrated an exceptional safety profile, with no significant toxicity observed in animal models.
Despite decades of research, BPC-157 remains not approved by the FDA or any major regulatory body for human use as of 2024.

How It Works

BPC-157 functions through multiple biological pathways, promoting angiogenesis, reducing inflammation, and enhancing tissue repair at the cellular level. Its mechanism is complex, involving interactions with growth factors, nitric oxide pathways, and the stabilization of blood vessels.

Angiogenesis stimulation: BPC-157 promotes the formation of new blood vessels, increasing blood flow to injured tissues and accelerating healing in rat tendon and muscle studies.
VEGF activation: It upregulates Vascular Endothelial Growth Factor, a key protein involved in blood vessel repair, by up to 40% in injured tissues within 72 hours.
Anti-inflammatory effects: BPC-157 reduces levels of pro-inflammatory cytokines like TNF-alpha by up to 50% in rodent models of colitis.
Gut barrier protection: It strengthens intestinal tight junctions, reducing intestinal permeability and preventing bacterial translocation in ulcerative conditions.
Tendon healing: In studies on rats with torn Achilles tendons, BPC-157 improved healing speed and strength by 30–40% compared to controls.
Neuroprotective action: The peptide crosses the blood-brain barrier and has shown protective effects in models of traumatic brain injury and nerve crush injuries.

Comparison at a Glance

Below is a comparison of BPC-157 with other commonly studied healing peptides:

Peptide	Primary Use	Year Discovered	Regulatory Status	Half-Life (Hours)
BPC-157	Tissue repair, gut health	1990	Not approved (research only)	~10–12
GHK-Cu	Skin regeneration, anti-aging	1973	Available in cosmetics	~4–5
Thymosin Beta-4	Anti-inflammatory, cardiac repair	1983	Research phase	~3–4
IGF-1	Muscle growth, tissue repair	1978	Prescription only	~1–2
Sermorelin	HGH stimulation	1990	Approved for diagnostics	~1–2

This table highlights BPC-157’s relatively long half-life and unique focus on gastrointestinal and musculoskeletal healing. While other peptides like IGF-1 and GHK-Cu are more widely known, BPC-157 stands out for its broad-spectrum regenerative effects and safety in animal studies. However, its lack of regulatory approval limits clinical use, unlike GHK-Cu, which is included in some FDA-compliant skincare products.

Why It Matters

Understanding the origins and potential of BPC-157 is crucial for researchers and patients interested in regenerative medicine. Though not yet approved for human use, its consistent performance in preclinical trials has generated significant interest in the medical and athletic communities.

BPC-157 could revolutionize treatment for tendon injuries, which typically heal slowly and often require surgery.
Its ability to heal intestinal permeability makes it a candidate for treating conditions like leaky gut syndrome.
Studies show it may support recovery from NSAID-induced ulcers, a common side effect of chronic pain medication.
The peptide has demonstrated efficacy in nerve regeneration, offering hope for peripheral nerve damage treatment.
Its anti-inflammatory action is comparable to corticosteroids but without the associated side effects like tissue atrophy.
As of 2023, over 160 peer-reviewed studies have documented its healing effects, primarily in rodent models.

Despite the promising data, the absence of large-scale human trials means BPC-157 remains in the research phase. Its future depends on rigorous clinical testing and regulatory evaluation, but its discovery in the 1990s laid the foundation for a new class of regenerative therapeutics.